Results 81 to 90 of about 7,834 (208)
Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs
Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri +10 more
wiley +1 more source
Frontiers in PharmacologyBackgroundConsidering the role PARPs play in inflammation, we assessed the effect of PARP inhibition in an inflammatory skin condition, psoriasis, to explore novel avenues for the potential repurposing of PARP inhibitors that are currently used in tumour
Petra Molnár +11 more
doaj +1 more source
Advances in the use of PARP inhibitor therapy for breast cancer
Drugs in Context, 2018 Poly-ADP-ribose polymerase 1 (PARP-1) and PARP-2 are DNA damage sensors that are most active during S-phase of the cell cycle and that have wider-reaching roles in DNA repair than originally described.
Kelly E McCann, Sara A Hurvitz
doaj +1 more source
Targeted Therapies for Ovarian Cancer [PDF]
, 2016 Epithelial ovarian cancer has the highest mortality rate of all gynaecological malignancies. Most women present with advanced disease and develop a recurrence after radical surgery and chemotherapy.
Grunewald, T, Ledermann, JA
core
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial [PDF]
, 2018 Background Patients with metastatic castration-resistant prostate cancer and homologous recombination repair (HRR) mutations have a better response to treatment with the poly(ADP-ribose) polymerase inhibitor olaparib than patients without HRR mutations ...
Alekseev, Boris +15 more
core +2 more sources
Evidence to date: talazoparib in the treatment of breast cancer.
OncoTargets and therapy, 2019 Approximately 5-10% of all patients diagnosed with breast cancer have germline BRCA1/2 mutations, which make their disease more susceptible to DNA-damaging agents and a new class of drugs known as poly(ADP-ribose) polymerase (PARP) inhibitors. Talazoparib is a new PARP inhibitor that has been recently approved for use in patients with metastatic breast
Exman,Pedro +2 more
openaire +3 more sources
Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation
MedComm – Oncology, Volume 5, Issue 2, June 2026.The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong +4 more
wiley +1 more source
Frontiers in Oncology, 2021 Renal cell carcinoma (RCC) is the sixth most common cancer in the US. However, no significant changes in management have occurred since the tyrosine kinase era until the recent breakthrough with checkpoint inhibitors.
Jerred P. Pletcher +11 more
doaj +1 more source
BET-inhibitor I-BET762 and PARP-inhibitor talazoparib synergy in small cell lung cancer cells [PDF]
, 2020 Small cell lung cancer (SCLC) is an aggressive type of lung cancer with high mortality that is caused by frequent relapses and acquired resistance.
Bagella L. +5 more
core +1 more source
Histopathology, Volume 88, Issue 7, Page 1373-1384, June 2026.In the real‐world VANESSA study in triple‐negative breast cancer, PD‐L1‐positive prevalence was 38% in early‐stage and 20% in metastatic tumours, lower than in prospective trials. The lower prevalence in smaller versus larger tissue samples and by local versus central assessment underlines the importance of robust PD‐L1 testing to determine eligibility
Corrado D'Arrigo +16 more
wiley +1 more source